+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Carbapenem Market Size, Share & Trends Analysis Report By Drug Class (Meropenem, Imipenem, Ertapenem), By Application (UTI, Blood Stream Infections, Pneumonia), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 236 Pages
  • September 2023
  • Region: Global
  • Grand View Research
  • ID: 5893238
Description Jump to:
The global carbapenem market size is expected to reach USD 5.24 billion by 2030., exhibiting a CAGR of 4.78% from 2023 to 2030. The rise in the utilization of carbapenem-based antibiotics, elevated prescription rates of antibiotics, and progress in research and development resulting in the upcoming novel medications; are a few of the factors that are anticipated to propel the growth of the market over the forecast period.

According to an American Lung Association article, published in November 2022, Pneumonia is more prevalent than commonly perceived, leading to over a million hospitalizations and causing more than 50, 000 deaths annually. In May 2023, Antabio initiated its Phase I trial by administering the initial dose of antibiotic therapy to healthy volunteers for hospital-acquired infections. The therapy, known as MEM-ANT3310, combines meropenem (MEM) with Antabio's novel broad-spectrum serine beta-lactamase inhibitor, ANT3310. This is fueling the growth of the market over the forecast period.

Moreover, during the pandemic, healthcare systems worldwide faced immense challenges in managing severe cases of COVID-19, especially in ICU settings. Many critically ill COVID-19 patients required advanced medical care, including the use of antibiotics to address secondary bacterial infections. Carbapenems, being potent broad-spectrum antibiotics, were one of the treatment options considered for bacterial co-infections in these patients. Thus, there was a significant impact during the period of the COVID-19 pandemic on the market.

The regulatory framework for pharmaceuticals in North America, particularly in the United States, is well-established and provides a clear pathway for drug approvals. For instance, in August 2022, Brooks Laboratories made an announcement stating that its subsidiary, Brooks Steriscience, has obtained approval from the United States Food & Drug Administration (USFDA) for the product, Meropenem Injection, available in 500mg per vial and 1gram per vial. This product serves as the generic equivalent to Pfizer Inc.'s Merrem Injection.

However, the overuse and misuse of antibiotics, including carbapenems, contribute to the development of antimicrobial resistance (AMR). As bacteria continue to evolve and become resistant to these drugs, their effectiveness in treating infections diminishes, posing a significant challenge for carbapenems and other antibiotics.

Carbapenem Market Report Highlights

  • Based on drug class, the meropenem segment dominated the market in 2022, owing to their broad-spectrum activity against various bacteria, including multidrug-resistant strains. Other segment is anticipated to grow at the fastest CAGR rate
  • Based on application, the urinary tract infections (UTIs) segment held the largest share of the market in 2022 and is anticipated to grow at the fastest growth rate. UTIs are considered to be the most common bacterial infections across the globe
  • Based on the distribution channel, the hospital pharmacies segment dominated the market in 2022 and is anticipated to grow at the fastest CAGR rate owing to the rising prevalence of bacterial infections
  • In 2022, North America dominated the market, owing to the presence of major market players, and robust healthcare infrastructure. These are anticipated to boost the market for carbapenem in the region over the forecast period
  • Asia Pacific is anticipated to grow at the fastest growth rate over the forecast period due to the high prevalence of UTIs, growing healthcare spending, and the development of healthcare infrastructure in developing countries like India and China


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Carbapenem Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Product Type Segment
1.1.1.2. Drug Class Segment
1.1.1.3. Application Segment
1.1.1.4. Distribution Channel Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Carbapenem Market: Executive Summary
2.1. Market Snapshot
2.2. Product Type and Application Snapshot
2.3. Distribution Channel Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Carbapenem Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Increasing prevalence of antibiotic-resistant infections
3.4.2. High R&D investments in clinical research
3.5. Market Restraint Analysis
3.5.1. High cost of production of carbapenem-based antibiotics
3.5.2. Side effects and safety concerns
3.6. Porter’s Five Forces Analysis
3.7. PESTLE Analysis
Chapter 4. Carbapenem Market: Drug Class Estimates & Trend Analysis
4.1. Carbapenem Market: Drug Class Movement Analysis
4.2. Meropenem
4.2.1. Meropenem Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3. Imipenem
4.3.1. Imipenem Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Ertapenem
4.4.1. Ertapenem Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Others
4.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Carbapenem Market: Application Estimates & Trend Analysis
5.1. Carbapenem Market: Application Movement Analysis
5.2. Urinary Tract Infections
5.2.1. Urinary Tract Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3. Bloodstream Infections
5.3.1. Bloodstream Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Intra-abdominal Infections
5.4.1. Intra-abdominal Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Pneumonia
5.5.1. Pneumonia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Others
5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Carbapenem Market: Distribution Channel Estimates & Trend Analysis
6.1. Carbapenem Market: Distribution Channel Movement Analysis
6.2. Hospital Pharmacies
6.2.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3. Retail Pharmacies
6.3.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Others
6.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Carbapenem Market: Regional Business Analysis
7.1. Regional Market Snapshot
7.2. North America
7.2.1. North America Carbapenem Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Carbapenem Market, 2018 - 2030 (USD Million)
7.2.2.2. Key Country Dynamics
7.2.2.3. Regulatory Framework
7.2.2.4. Reimbursement Scenario
7.2.2.5. Competitive Scenario
7.2.3. Canada
7.2.3.1. Canada Carbapenem Market, 2018 - 2030 (USD Million)
7.2.3.2. Key Country Dynamics
7.2.3.3. Regulatory Framework
7.2.3.4. Reimbursement Scenario
7.2.3.5. Competitive Scenario
7.3. Europe
7.3.1. Europe Carbapenem Market, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Carbapenem Market, 2018 - 2030 (USD Million)
7.3.2.2. Key Country Dynamics
7.3.2.3. Regulatory Framework
7.3.2.4. Reimbursement Scenario
7.3.2.5. Competitive Scenario
7.3.3. Germany
7.3.3.1. Germany Carbapenem Market, 2018 - 2030 (USD Million)
7.3.3.2. Key Country Dynamics
7.3.3.3. Regulatory Framework
7.3.3.4. Reimbursement Scenario
7.3.3.5. Competitive Scenario
7.3.4. Spain
7.3.4.1. Spain Carbapenem Market, 2018 - 2030 (USD Million)
7.3.4.2. Key Country Dynamics
7.3.4.3. Regulatory Framework
7.3.4.4. Reimbursement Scenario
7.3.4.5. Competitive Scenario
7.3.5. France
7.3.5.1. France Carbapenem Market, 2018 - 2030 (USD Million)
7.3.5.2. Key Country Dynamics
7.3.5.3. Regulatory Framework
7.3.5.4. Reimbursement Scenario
7.3.5.5. Competitive Scenario
7.3.6. Italy
7.3.6.1. Italy Carbapenem Market, 2018 - 2030 (USD Million)
7.3.6.2. Key Country Dynamics
7.3.6.3. Regulatory Framework
7.3.6.4. Reimbursement Scenario
7.3.6.5. Competitive Scenario
7.3.7. Denmark
7.3.7.1. Denmark Carbapenem Market, 2018 - 2030 (USD Million)
7.3.7.2. Key Country Dynamics
7.3.7.3. Regulatory Framework
7.3.7.4. Reimbursement Scenario
7.3.7.5. Competitive Scenario
7.3.8. Sweden
7.3.8.1. Sweden Carbapenem Market, 2018 - 2030 (USD Million)
7.3.8.2. Key Country Dynamics
7.3.8.3. Regulatory Framework
7.3.8.4. Reimbursement Scenario
7.3.8.5. Competitive Scenario
7.3.9. Norway
7.3.9.1. Norway Carbapenem Market, 2018 - 2030 (USD Million)
7.3.9.2. Key Country Dynamics
7.3.9.3. Regulatory Framework
7.3.9.4. Reimbursement Scenario
7.3.9.5. Competitive Scenario
7.4. Asia Pacific
7.4.1. Asia-Pacific Carbapenem Market, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Japan Carbapenem Market, 2018 - 2030 (USD Million)
7.4.2.2. Key Country Dynamics
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Scenario
7.4.2.5. Competitive Scenario
7.4.3. China
7.4.3.1. China Carbapenem Market, 2018 - 2030 (USD Million)
7.4.3.2. Key Country Dynamics
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Scenario
7.4.3.5. Competitive Scenario
7.4.4. India
7.4.4.1. India Carbapenem Market, 2018 - 2030 (USD Million)
7.4.4.2. Key Country Dynamics
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Scenario
7.4.4.5. Competitive Scenario
7.4.5. South Korea
7.4.5.1. South Korea Carbapenem Market, 2018 - 2030 (USD Million)
7.4.5.2. Key Country Dynamics
7.4.5.3. Regulatory Framework
7.4.5.4. Reimbursement Scenario
7.4.5.5. Competitive Scenario
7.4.6. Thailand
7.4.6.1. Thailand Carbapenem Market, 2018 - 2030 (USD Million)
7.4.6.2. Key Country Dynamics
7.4.6.3. Regulatory Framework
7.4.6.4. Reimbursement Scenario
7.4.6.5. Competitive Scenario
7.4.7. Australia
7.4.7.1. Australia Carbapenem Market, 2018 - 2030 (USD Million)
7.4.7.2. Key Country Dynamics
7.4.7.3. Regulatory Framework
7.4.7.4. Reimbursement Scenario
7.4.7.5. Competitive Scenario
7.5. Latin America
7.5.1. Latin America Carbapenem Market, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Carbapenem Market, 2018 - 2030 (USD Million)
7.5.2.2. Key Country Dynamics
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Scenario
7.5.2.5. Competitive Scenario
7.5.3. Mexico
7.5.3.1. Mexico Carbapenem Market, 2018 - 2030 (USD Million)
7.5.3.2. Key Country Dynamics
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Scenario
7.5.3.5. Competitive Scenario
7.5.4. Argentina
7.5.4.1. Argentina Carbapenem Market, 2018 - 2030 (USD Million)
7.5.4.2. Key Country Dynamics
7.5.4.3. Regulatory Framework
7.5.4.4. Reimbursement Scenario
7.5.4.5. Competitive Scenario
7.6. MEA
7.6.1. MEA Carbapenem Market, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Carbapenem Market, 2018 - 2030 (USD Million)
7.6.2.2. Key Country Dynamics
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Scenario
7.6.2.5. Competitive Scenario
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Carbapenem Market, 2018 - 2030 (USD Million)
7.6.3.2. Key Country Dynamics
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Scenario
7.6.3.5. Competitive Scenario
7.6.4. UAE
7.6.4.1. UAE Carbapenem Market, 2018 - 2030 (USD Million)
7.6.4.2. Key Country Dynamics
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Scenario
7.6.4.5. Competitive Scenario
7.6.5. Kuwait
7.6.5.1. Kuwait Carbapenem Market, 2018 - 2030 (USD Million)
7.6.5.2. Key Country Dynamics
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Scenario
7.6.5.5. Competitive Scenario
Chapter 8. Carbapenem Market: Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.2.1. New Product Type Launch
8.2.2. Partnerships
8.2.3. Acquisition
8.2.4. Collaborotion
8.2.5. Funding
8.3. Key Company Market Share Analysis, 2022
8.4. Company Heat Map Analysis
8.5. Company Profiles
8.5.1. The Menarini Group
8.5.1.1. Company Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Pfizer Inc.
8.5.2.1. Company Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Sun Pharmaceutical Industries Ltd
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Lupin
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Kopran Limited
8.5.5.1. Company Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Aurobindo Pharma
8.5.6.1. Company Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Daewoong Pharmaceuticals Co., Ltd.
8.5.7.1. Company Overview
8.5.7.2. Product Benchmarking
8.5.7.3. Strategic Initiatives
8.5.8. Shenzhen Haibin Pharmaceutical Co. Ltd.
8.5.8.1. Company Overview
8.5.8.2. Product Benchmarking
8.5.8.3. Strategic Initiatives
8.5.9. Merck & Co., Inc.
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Venus Remedies Ltd
8.5.10.1. Company Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 1 List of abbreviation
Table 2 North America carbapenem market, by country, 2018 - 2030 (USD Million)
Table 3 North America carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 4 North America carbapenem market, by application, 2018 - 2030 (USD Million)
Table 5 North America carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 6 U.S. carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 7 U.S carbapenem market, by application, 2018 - 2030 (USD Million)
Table 8 U.S carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 9 Canada carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 10 Canada carbapenem market, by application, 2018 - 2030 (USD Million)
Table 11 Canada carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 12 Europe carbapenem market, by country, 2018 - 2030 (USD Million)
Table 13 Europe carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 14 Europe carbapenem market, by application, 2018 - 2030 (USD Million)
Table 15 Europe carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 16 UK carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 17 UK carbapenem market, by application, 2018 - 2030 (USD Million)
Table 18 UK carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 19 Germany carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 20 Germany carbapenem market, by application, 2018 - 2030 (USD Million)
Table 21 Germany carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 22 France carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 23 France carbapenem market, by application, 2018 - 2030 (USD Million)
Table 24 France carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 Italy carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 26 Italy carbapenem market, by application, 2018 - 2030 (USD Million)
Table 27 Italy carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 28 Spain carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 29 Spain carbapenem market, by application, 2018 - 2030 (USD Million)
Table 30 Spain carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 31 Denmark carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 32 Denmark carbapenem market, by application, 2018 - 2030 (USD Million)
Table 33 Denmark carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Sweden carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 35 Sweden carbapenem market, by application, 2018 - 2030 (USD Million)
Table 36 Sweden carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 37 Norway carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 38 Norway carbapenem market, by application, 2018 - 2030 (USD Million)
Table 39 Norway carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 40 Asia Pacific carbapenem market, by country, 2018 - 2030 (USD Million)
Table 41 Asia Pacific carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 42 Asia Pacific carbapenem market, by application, 2018 - 2030 (USD Million)
Table 43 Asia Pacific carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 44 China carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 45 China carbapenem market, by application, 2018 - 2030 (USD Million)
Table 46 China carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 47 Japan carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 48 Japan carbapenem market, by application, 2018 - 2030 (USD Million)
Table 49 Japan carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 50 India carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 51 India carbapenem market, by application, 2018 - 2030 (USD Million)
Table 52 India carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 53 South Korea carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 54 South Korea carbapenem market, by application, 2018 - 2030 (USD Million)
Table 55 South Korea carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 56 Australia carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 57 Australia carbapenem market, by application, 2018 - 2030 (USD Million)
Table 58 Australia carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 59 Thailand carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 60 Thailand carbapenem market, by application, 2018 - 2030 (USD Million)
Table 61 Thailand carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Latin America carbapenem market, by country, 2018 - 2030 (USD Million)
Table 63 Latin America carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 64 Latin America carbapenem market, by application, 2018 - 2030 (USD Million)
Table 65 Latin America carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 66 Brazil carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 67 Brazil carbapenem market, by application, 2018 - 2030 (USD Million)
Table 68 Brazil carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 69 Mexico carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 70 Mexico carbapenem market, by application, 2018 - 2030 (USD Million)
Table 71 Mexico carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 72 Argentina carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 73 Argentina carbapenem market, by application, 2018 - 2030 (USD Million)
Table 74 Argentina carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 75 Middle East & Africa carbapenem market, by country, 2018 - 2030 (USD Million)
Table 76 Middle East & Africa carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 77 Middle East & Africa carbapenem market, by application, 2018 - 2030 (USD Million)
Table 78 Middle East & Africa carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 79 South Africa carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 80 South Africa carbapenem market, by application, 2018 - 2030 (USD Million)
Table 81 South Africa carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia carbapenem market, by application, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 85 UAE carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 86 UAE carbapenem market, by application, 2018 - 2030 (USD Million)
Table 87 UAE carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
Table 88 Kuwait carbapenem market, by drug class, 2018 - 2030 (USD Million)
Table 89 Kuwait carbapenem market, by application, 2018 - 2030 (USD Million)
Table 90 Kuwait carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market summary
Fig. 4 Market segmentation & scope
Fig. 5 Market size and growth prospects
Fig. 6 Global carbapenem market - Key market driver analysis
Fig. 7 Global carbapenem market - Key market restraint analysis
Fig. 8 Penetration & growth prospect mapping
Fig. 9 Global carbapenem market - Porter’s analysis
Fig. 10 Global carbapenem market - PESTEL analysis
Fig. 11 Global carbapenem market drug class outlook key takeaways
Fig. 12 Global carbapenem market: Drug class movement analysis
Fig. 13 Meropenem market estimates, 2018 - 2030 (USD Million)
Fig. 14 Imipenem market estimates, 2018 - 2030 (USD Million)
Fig. 15 Ertapenem market estimates, 2018 - 2030 (USD Million)
Fig. 16 Others market estimates, 2018 - 2030 (USD Million)
Fig. 17 Global carbapenem market application outlook key takeaways
Fig. 18 Global carbapenem market: application movement analysis
Fig. 19 Urinary tract infections market estimates, 2018 - 2030 (USD Million)
Fig. 20 Bloodstream infections market estimates, 2018 - 2030 (USD Million)
Fig. 21 Pneumonia market estimates, 2018 - 2030 (USD Million)
Fig. 22 Intra - abdominal infections market estimates, 2018 - 2030 (USD Million)
Fig. 23 Others market estimates, 2018 - 2030 (USD Million)
Fig. 24 Global carbapenem market distribution channel outlook key takeaways
Fig. 25 Global carbapenem market: Test type movement analysis
Fig. 26 Hospital pharmacies market estimates, 2018 - 2030 (USD Million)
Fig. 27 Retail pharmacies market estimates, 2018 - 2030 (USD Million)
Fig. 28 Others market estimates, 2018 - 2030 (USD Million)
Fig. 29 Regional marketplace: Key takeaways
Fig. 30 Global carbapenem market: Regional movement analysis
Fig. 31 North America carbapenem market, 2018 - 2030 (USD Million)
Fig. 32 U.S. carbapenem market, 2018 - 2030 (USD Million)
Fig. 33 Canada carbapenem market, 2018 - 2030 (USD Million)
Fig. 34 Europe carbapenem market, 2018 - 2030 (USD Million)
Fig. 35 UK carbapenem market, 2018 - 2030 (USD Million)
Fig. 36 Germany carbapenem market, 2018 - 2030 (USD Million)
Fig. 37 France carbapenem market, 2018 - 2030 (USD Million)
Fig. 38 Spain carbapenem market, 2018 - 2030 (USD Million)
Fig. 39 Italy carbapenem market, 2018 - 2030 (USD Million)
Fig. 40 Denmark carbapenem market, 2018 - 2030 (USD Million)
Fig. 41 Sweden carbapenem market, 2018 - 2030 (USD Million)
Fig. 42 Norway carbapenem market, 2018 - 2030 (USD Million)
Fig. 43 Asia Pacific carbapenem market, 2018 - 2030 (USD Million)
Fig. 44 Japan carbapenem market, 2018 - 2030 (USD Million)
Fig. 45 China carbapenem market, 2018 - 2030 (USD Million)
Fig. 46 India carbapenem market, 2018 - 2030 (USD Million)
Fig. 47 South Korea carbapenem market, 2018 - 2030 (USD Million)
Fig. 48 Australia carbapenem market, 2018 - 2030 (USD Million)
Fig. 49 Thailand carbapenem market, 2018 - 2030 (USD Million)
Fig. 50 Latin America carbapenem market, 2018 - 2030 (USD Million)
Fig. 51 Brazil carbapenem market, 2018 - 2030 (USD Million)
Fig. 52 Mexico carbapenem market, 2018 - 2030 (USD Million)
Fig. 53 Argentina carbapenem market, 2018 - 2030 (USD Million)
Fig. 54 MEA carbapenem market, 2018 - 2030 (USD Million)
Fig. 55 South Africa carbapenem market, 2018 - 2030 (USD Million)
Fig. 56 Saudi Arabia carbapenem market, 2018 - 2030 (USD Million)
Fig. 57 UAE carbapenem market, 2018 - 2030 (USD Million)
Fig. 58 Kuwait carbapenem market, 2018 - 2030 (USD Million)
Fig. 59 Strategy framework

Companies Mentioned

  • The Menarini Group
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Lupin
  • Kopran Limited
  • Aurobindo Pharma
  • Daewoong Pharmaceuticals Co., Ltd.
  • Shenzhen Haibin Pharmaceutical Co. Ltd.
  • Merck & Co., Inc.
  • Venus Remedies Ltd

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages236
PublishedSeptember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 3.62 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.24 Billion
Compound Annual Growth Rate4.7%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Carbapenem-based Antibiotics Global Market Report 2024 - Product Image

Carbapenem-based Antibiotics Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Carbapenem Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Carbapenem Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 181 Pages
  • Global
From
Carbapenem-Resistant Enterobacteriaceae - Pipeline Insight, 2024 - Product Image

Carbapenem-Resistant Enterobacteriaceae - Pipeline Insight, 2024

  • Drug Pipelines
  • 70 Pages
  • Global
From
Carbapenem-Resistant Enterobacteriaceae (CRE) Infection - Pipeline Insight, 2024 - Product Image

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
Global Beta Lactam & Beta Lactamase Inhibitors Market by Drug Class (Carbapenem, Cephalosporins, Monobactam), Disease (Blood Stream Infection, Complicated Intra-Abdominal Infections (cIAI), Complicated Urinary Tract Infection (cUTI)), Route of Administration - Forecast 2024-2030 - Product Image

Global Beta Lactam & Beta Lactamase Inhibitors Market by Drug Class (Carbapenem, Cephalosporins, Monobactam), Disease (Blood Stream Infection, Complicated Intra-Abdominal Infections (cIAI), Complicated Urinary Tract Infection (cUTI)), Route of Administration - Forecast 2024-2030

  • Report
  • 198 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.